As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial
Health regulators are being urged to rapidly approve two gamechanging dementia drugs in order to ensure millions of people who could benefit are not “left in limbo” after yet more stunning trial data.
The call from experts came as the final results from a landmark study confirmed that donanemab, made by Eli Lilly, slowed cognitive decline in Alzheimer’s patients by 35%. Trial results published last year showed that a second drug, lecanemab, made by Eisai and Biogen, reduced the rate by 27%.
